α-galactosylceramide as a therapeutic agent for pulmonary Mycobacterium tuberculosis infection

American Journal of Respiratory and Critical Care Medicine

Volumn 182, Issue 6, 2010, Pages 841-847

  Sada Ovalle, Isabel ^a,c   Sköld, Markus ^a,d   Tian, Tian ^a   Besra, Gurdyal S ^b   Behar, Samuel M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c Immunochemistry Department   (United States)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Antibiotics; CD1d; Lipids; Natural killer T cells; Tuberculosis

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; GAMMA INTERFERON; ISONIAZID; ALPHA-GALACTOSYLCERAMIDE; CD1D ANTIGEN; GALACTOSYLCERAMIDE; TUBERCULOSTATIC AGENT;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ACTIVATION; COLONY FORMING UNIT; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG DOSE COMPARISON; DRUG POTENTIATION; FEMALE; GROWTH INHIBITION; IMMUNE RESPONSE; LUNG TUBERCULOSIS; MICROBIAL GROWTH; MOUSE; NATURAL KILLER CELL; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TREATMENT RESPONSE; ANIMAL; C3H MOUSE; C57BL MOUSE; DRUG COMBINATION; DRUG EFFECT; IMMUNOLOGY; IMMUNOMODULATION; MICROBIOLOGY; MYCOBACTERIUM TUBERCULOSIS; NATURAL KILLER T CELL; TREATMENT OUTCOME;

ANIMALS; ANTIGENS, CD1D; ANTITUBERCULAR AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GALACTOSYLCERAMIDES; IMMUNOMODULATION; ISONIAZID; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MYCOBACTERIUM TUBERCULOSIS; NATURAL KILLER T-CELLS; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 77957084122     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200912-1921OC     Document Type: Article

References (53)

1. Federal Tuberculosis Task Force. Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force. MMWR Recomm Rep 2009;58:1-43.
2. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, Fujiwara P, Grzemska M, Hopewell PC, Iseman MD, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-662.
3. Sada-Ovalle I, Chiba A, Gonzales A, Brenner MB, Behar SM. Innate invariant NKT cells recognize Mycobacterium tuberculosis-infected macrophages, produce interferon-gamma, and kill intracellular bacteria. PLoS Pathog 2008;4:e1000239.
4. Bendelac, A., Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol 2007;25:297-336.
5. Wu L, Gabriel CL, Parekh VV, Van KL. Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities. Tissue Antigens 2009;73:535-545.
6. Hegde S, Jankowska-Gan E, Roenneburg DA, Torrealba J, Burlingham WJ, Gumperz JE. Human NKT cells promote monocyte differentiation into suppressive myeloid antigen-presenting cells. J Leukoc Biol 2009;86:757-768.
7. Akbari O, Stock P, Meyer E, Kronenberg M, Sidobre S, Nakayama T, Taniguchi M, Grusby MJ, DeKruyff RH, Umetsu DT. Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity. Nat Med 2003;9:582-588.
8. Chan WL, Pejnovic N, Liew TV, Lee CA, Groves R, Hamilton H. NKT cell subsets in infection and inflammation. Immunol Lett 2003;85: 159-163.
9. Van KL. alpha-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles. Nat Rev Immunol 2005;5:31-42.
10. Kitamura H, Iwakabe K, Yahata T, Nishimura S, Ohta A, Ohmi Y, Sato M, Takeda K, Okumura K, Van Kaer L, et al. The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J Exp Med 1999;189:1121-1128.
11. Eberl G, MacDonald HR. Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells. Eur J Immunol 2000;30: 985-992.
12. Kitamura, H., Ohta A, Sekimoto M, Sato M, Iwakabe K, Nakui M, Yahata T, Meng H, Koda T, Nishimura S, et al. 2000. alpha-Galactosylceramide induces early B-cell activation through IL-4 production by NKT cells. Cell Immunol 2000;199:37-42.
13. Nishimura T, Kitamura H, Iwakabe K, Yahata T, Ohta A, Sato M, Takeda K, Okumura K, Van KL, Kawano T, et al. The interface between innate and acquired immunity: glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes. Int Immunol 2000;12:987-994.
14. Kunii N, Horiguchi S, Motohashi S, Yamamoto H, Ueno N, Yamamoto S, Sakurai D, Taniguchi M, Nakayama T, Okamoto Y. Combination therapy of in vitro-expanded natural killer T cells and alpha-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma. Cancer Sci 2009;100:1092-1098.
15. Choi YS, Hoory T, Monie A, Wu A, Connolly D, Hung CF. alpha-Galactosylceramide enhances the protective and therapeutic effects of tumor cell based vaccines for ovarian tumors. Vaccine 2008;26: 5855-5863.
16. Motohashi S, Nagato K, Kunii N, Yamamoto H, Yamasaki K, Okita K, Hanaoka H, Shimizu N, Suzuki M, Yoshino I, et al. A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer. J Immunol 2009;182:2492-2501.
17. Van Der Vliet HJ, Molling JW, Von Blomberg BM, Nishi N, Kolgen W, Van Den Eertwegh AJ, Pinedo HM, Giaccone G, Scheper RJ. The immunoregulatory role of CD1d-restricted natural killer T cells in disease. Clin Immunol 2004;112:8-23.
18. Gilleron M, Ronet C, Mempel M, Monsarrat B, Gachelin G, Puzo G. Acylation state of the phosphatidylinositol mannosides from Mycobacterium bovis bacillus Calmette Guerin and ability to induce granuloma and recruit natural killer T cells. J Biol Chem 2001;276: 34896-34904.
19. Skold M, Xiong X, Illarionov PA, Besra GS, Behar SM. Interplay of cytokines and microbial signals in regulation of CD1d expression and NKT cell activation. J Immunol 2005;175:3584-3593.
20. Sousa AO, Mazzaccaro RJ, Russell RG, Lee FK, Turner OC, Hong S, Van Kaer L, Bloom BR. Relative contributions of distinct MHC class I-dependent cell populations in protection to tuberculosis infection in mice. Proc Natl Acad Sci USA 2000;97:4204-4208.
21. D'Souza CD, Cooper AM, Frank AA, Ehlers S, Turner J, Bendelac A, Orme IM. A novel nonclassic beta2-microglobulin-restricted mechanism influencing early lymphocyte accumulation and subsequent resistance to tuberculosis in the lung. Am J Respir Cell Mol Biol 2000;23:188-193.
22. Chiba A, Dascher CC, Besra GS, Brenner MB. Rapid NKT cell responses are self-terminating during the course of microbial infection. J Immunol 2008;181:2292-2302.
23. Chackerian AA, Alt JM, Perera TV, Dascher CC, Behar SM. Dissemination of Mycobacterium tuberculosis is influenced by host factors and precedes the initiation of T-cell immunity. Infect Immun 2002;70: 4501-4509.
24. Brigl M, Bry L, Kent SC, Gumperz JE, Brenner MB. Mechanism of CD1d-restricted natural killer T cell activation during microbial infection. Nat Immunol 2003;4:1230-1237.
25. Chackerian AA, Perera TV, Behar SM. Gamma interferon-producing CD4(1) T lymphocytes in the lung correlate with resistance to infection with Mycobacterium tuberculosis. Infect Immun 2001;69: 2666-2674.
26. Medina E, North RJ. Resistance ranking of some common inbred mouse strains to Mycobacterium tuberculosis and relationship to major histocompatibility complex haplotype and Nramp1 genotype. Immunology 1998;93:270-274.
27. Pan H, Yan BS, Rojas M, Shebzukhov YV, Zhou H, Kobzik L, Higgins DE, Daly MJ, Bloom BR, Kramnik I. Ipr1 gene mediates innate immunity to tuberculosis. Nature 2005;434:767-772.
28. Chackerian A, Alt J, Perera V, Behar SM. Activation of NKT cells protects mice from tuberculosis. Infect Immun 2002;70:6302-6309.
29. Kimura T, Ishii Y, Morishima Y, Shibuya A, Shibuya K, Taniguchi M, Mochizuki M, Hegab AE, Sakamoto T, Nomura A, et al. Treatment with alpha-galactosylceramide attenuates the development of bleomycin-induced pulmonary fibrosis. J Immunol 2004;172:5782-5789.
30. Schmieg J, Yang G, Franck RW, Tsuji M. Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand alpha-Galactosylceramide. J Exp Med 2003;198:1631-1641.
31. Johnson BJ, Bekker LG, Rickman R, Brown S, Lesser M, Ress S, Willcox P, Steyn L, Kaplan G. rhuIL-2 adjunctive therapy in multidrug resistant tuberculosis: a comparison of two treatment regimens and placebo. Tuber Lung Dis 1997;78:195-203.
32. Suarez-Mendez R, Garcia-Garcia I, Fernandez-Olivera N, Valdes-Quintana M, Milanes-Virelles MT, Carbonell D, Machado-Molina D, Valenzuela-Silva CM, Lopez-Saura PA. Adjuvant interferon gamma in patients with drug - resistant pulmonary tuberculosis: a pilot study. BMC Infect Dis 2004;4:44.
33. Park SK, Cho S, Lee IH, Jeon DS, Hong SH, Smego RA, Cho SN. Subcutaneously administered interferon-gamma for the treatment of multidrug-resistant pulmonary tuberculosis. Int J Infect Dis 2007;11: 434-440.
34. Dawson R, Condos R, Tse D, Huie ML, Ress S, Tseng CH, Brauns C, Weiden M, Hoshino Y, Bateman E, et al. Immunomodulation with recombinant interferon-gamma1b in pulmonary tuberculosis. PLoS ONE 2009;4:e6984.
35. Johnson JL, Ssekasanvu E, Okwera A, Mayanja H, Hirsch CS, Nakibali JG, Jankus DD, Eisenach KD, Boom WH, Ellner JJ, et al. Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis. Am J Respir Crit Care Med 2003;168:185-191.
36. Greinert U, Ernst M, Schlaak M, Entzian P. Interleukin-12 as successful adjuvant in tuberculosis treatment. Eur Respir J 2001;17:1049-1051.
37. Tramontana JM, Utaipat U, Molloy A, Akarasewi P, Burroughs M, Makonkawkeyoon S, Johnson B, Klausner JD, Rom W, Kaplan G. Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med 1995;1:384-397.
38. Raju B, Hoshino Y, Kuwabara K, Belitskaya I, Prabhakar S, Canova A, Gold JA, Condos R, Pine RI, Brown S, et al. Aerosolized gamma interferon (IFN-gamma) induces expression of the genes encoding the IFN-gamma-inducible 10-kilodalton protein but not inducible nitric oxide synthase in the lung during tuberculosis. Infect Immun 2004;72: 1275-1283.
39. Bekker LG, Haslett P, Maartens G, Steyn L, Kaplan G. Thalidomide-induced antigen-specific immune stimulation in patients with human immunodeficiency virus type 1 and tuberculosis. J Infect Dis 2000;181: 954-965.
40. Wilson SB, Delovitch TL. Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity. Nat Rev Immunol 2003;3: 211-222.
41. Hammond KJ, Godfrey DI. NKT cells: potential targets for autoimmune disease therapy? Tissue Antigens 2002;59:353-363.
42. Kawakami K, Kinjo Y, Yara S, Koguchi Y, Uezu K, Nakayama T, Taniguchi M, Saito A. Activation of V alpha14(+) natural killer T cells by alpha-galactosylceramide results in development of Th1 response and local host resistance in mice infected with Cryptococcus neoformans. Infect Immun 2001;69:213-220.
43. Nieuwenhuis EE, Matsumoto T, Exley M, Schleipman RA, Glickman J, Bailey DT, Corazza N, Colgan SP, Onderdonk AB, Blumberg RS. CD1d-dependent macrophage-mediated clearance of Pseudomonas aeruginosa from lung. Nat Med 2002;8:588-593.
44. Stanley AC, Zhou Y, Amante FH, Randall LM, Haque A, Pellicci DG, Hill GR, Smyth MJ, Godfrey DI, Engwerda CR. Activation of invariant NKT cells exacerbates experimental visceral leishmaniasis. PLoS Pathog 2008;4:e1000028.
45. Fujii S, Liu K, Smith C, Bonito AJ, Steinman RM. The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J Exp Med 2004;199:1607-1618.
46. Venkataswamy MM, Baena A, Goldberg MF, Bricard G, Im JS, Chan J, Reddington F, Besra GS, Jacobs WR Jr, Porcelli SA. Incorporation of NKT cell-activating glycolipids enhances immunogenicity and vaccine efficacy of Mycobacterium bovis bacillus Calmette-Guerin. J Immunol 2009;183:1644-1656.
47. Kamijuku H, Nagata Y, Jiang X, Ichinohe T, Tashiro T, Mori K, Taniguchi M, Hase K, Ohno H, Shimaoka T, et al. Mechanism of NKT cell activation by intranasal coadministration of alpha-galactosylceramide, which can induce cross-protection against influenza viruses. Mucosal Immunol 2008;1:208-218.
48. Grajewski RS, Hansen AM, Agarwal RK, Kronenberg M, Sidobre S, Su SB, Silver PB, Tsuji M, Franck RW, Lawton AP, et al. Activation of invariant NKT cells ameliorates experimental ocular autoimmunity by a mechanism involving innate IFN-gamma production and dampening of the adaptive Th1 and Th17 responses. J Immunol 2008;181:4791-4797.
49. Carnaud C, Lee D, Donnars O, Park SH, Beavis A, Koezuka Y, Bendelac A. Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol 1999; 163:4647-4650.
50. Guillonneau C, Mintern JD, Hubert FX, Hurt AC, Besra GS, Porcelli SA, Barr IG, Doherty PC, Godfrey DI, Turner SJ. Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity. Proc Natl Acad Sci USA 2009; 106:3330-3335.
51. Gonzalez-Aseguinolaza G, de Oliveira C, Tomaska M, Hong S, Bruna-Romero O, Nakayama T, Taniguchi M, Bendelac A, Van Kaer L, Koezuka Y, et al. alpha -Galactosylceramide-activated Valpha 14 natural killer T cells mediate protection against murine malaria. Proc Natl Acad Sci USA 2000;97:8461-8466.
52. Cerundolo V, Silk JD, Masri SH, Salio M. Harnessing invariant NKT cells in vaccination strategies. Nat Rev Immunol 2009;9:28-38.
53. Motohashi S, Nakayama T. Clinical applications of natural killer T cell-based immunotherapy for cancer. Cancer Sci 2008;99:638-645.